Organon & Co. marked a -1.9% change today, compared to 0.0% for the S&P 500. Is it a good value at today's price of $16.91? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally.
-
Organon & Co. belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 24.45 and an average price to book (P/B) of 4.16
-
Organon & Co. has a trailing 12 month Price to Earnings (P/E) ratio of 5.7 based on its trailing 12 month price to earnings (EPS) of $2.95 per share
-
Its forward P/E ratio is 3.7, based on its forward earnings per share (EPS) of $4.59
-
OGN has a Price to Earnings Growth (PEG) ratio of -0.78, which shows the company has a fair value when we factor growth into the price to earnings calculus.
-
Over the last four years, Organon & Co. has averaged free cash flows of $1.7 Billion, which on average grew 0.0%
-
OGN's gross profit margins have averaged 62.5 % over the last four years and during this time they had a growth rate of -0.1 % and a coefficient of variability of 1.1 %.
-
Organon & Co. has moved -29.0% over the last year compared to 16.0% for the S&P 500 -- a difference of -45.0%
-
OGN has an average analyst rating of hold and is -44.67% away from its mean target price of $30.57 per share